Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00234195 · ClinicalTrials.gov registry record · Phase 4
Wellbutrin XL, Major Depressive Disorder and Breast Cancer
A Phase 4 study, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT00234195: Completed Phase 4 study, sponsored by Thomas Jefferson University.
NCT00234195 is a Phase 4 study that has completed, run by Thomas Jefferson University. The registered enrollment target is 25 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00234195, a Phase 4 study, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
* To evaluate the efficacy of bupropion extended release (Wellbutrin XL™) in the treatment of Major Depressive Disorder in women with breast cancer. * To evaluate the tolerability of bupropion extended-release (Wellbutrin XL™) in these patients
Interventions
- DRUG bupropion extended release (Wellbutrin XL)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-01 |
| Phase | Phase 4 |
What the finished NCT00234195 record still lists
NCT00234195 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which bupropion extended release (Wellbutrin XL) is the first listed.
NCT00234195 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00234195 about?
NCT00234195 is a clinical study titled "Wellbutrin XL, Major Depressive Disorder and Breast Cancer". * To evaluate the efficacy of bupropion extended release (Wellbutrin XL™) in the treatment of Major Depressive Disorder in women with breast cancer. * To evaluate the tolerability of bupropion extended-release (Wellbutrin XL™) in these patients
What is the current status of trial NCT00234195?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2005-09. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00234195?
The interventions under investigation include: bupropion extended release (Wellbutrin XL) (DRUG).
Who is sponsoring clinical trial NCT00234195?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00234195's enrollment target sits among peer trials
25 1669th of 2000 higher than 302 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia